Program
OPT101
A development code.
Its studies are mostly in Diabetes Mellitus, Type 1 · Sepsis, led by Op-T.
Furthest: phase 2, since Apr 14, 20254 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Op-T | 42 open or running | phase 2since Apr 14, 2025 | Oct 5, 2020 | May 31, 2027phase 2 · NCT06964087 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 5, 2020First study: phase 1 study in HealthyFirst studyNCT04589403 · 14 enrolled · United States
- Jun 9, 2022Phase 1 study in Diabetes Mellitus, Type 1NCT05428943 · 24 enrolled · United States
- Oct 28, 2024Phase 1 study in SepsisNCT06669403 · 26 planned · United States
- Apr 14, 2025Phase 2 study in Diabetes Mellitus, Type 1NCT06964087 · 72 planned · United States
Ahead
- May 31, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 1NCT06964087
TargetBeta
CD40LG →read by rule
“OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation.”study text, by rule · the study
Other programs on CD40LG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| frexalimab | Sanofi | phase 3 | 11 |
| dazodalibeprule | Amgen | phase 3 | 9 |
| dapirolizumab pegolrule | UCB | phase 3 | 8 |
| tegoprubartrule | eledon-pharmaceuticals | phase 3 | 8 |
| ravagalimabrule | AbbVie | phase 2 | 4 |
| TNX-1500rule | Tonix Pharmaceuticals | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06964087Diabetes Mellitus, Type 1 · United States | 2 | Recruiting | May 31, 2027 | 72 |
| NCT06669403Sepsis · United States | 1 | Not yet recruiting | Apr 2026 | 26 |
| NCT05428943Diabetes Mellitus, Type 1 · United States | 1 | Completed | Feb 21, 2024 | 24 |
| NCT04589403Healthy · United States | 1 | Completed | Sep 27, 2021 | 14 |
How it is read
Names in the registry
- “OPT101”, 4 entries
Codes read as this program: OPT101.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 2 studies
- Sepsis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.